Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors

NCT05348356 is registered in ClinicalTrials.gov with SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany as lead sponsor.

NCT NCT05348356
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05348356 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Nirogacestat in Patients With Recurrent Ovarian Granulosa Cell Tumors
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Phase
Phase 2
Overall status
Completed
Start date
August 30, 2022
Completion date
July 14, 2025
Enrollment
53 (actual)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer, ovarian granulosa cell tumor, ovarian granulosa-stromal tumor